share_log

Frontier Capital Management Co. LLC Makes New $64.17 Million Investment in Humana Inc. (NYSE:HUM)

Frontier Capital Management Co. LLC Makes New $64.17 Million Investment in Humana Inc. (NYSE:HUM)

FronTier Capital Management Co.LLC向Humana Inc.(紐約證券交易所代碼:HUM)新投資6417萬美元
Financial News Live ·  2022/09/29 11:32

Frontier Capital Management Co. LLC acquired a new position in Humana Inc. (NYSE:HUM – Get Rating) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 137,088 shares of the insurance provider's stock, valued at approximately $64,167,000. Humana accounts for 0.7% of Frontier Capital Management Co. LLC's holdings, making the stock its 27th biggest position. Frontier Capital Management Co. LLC owned approximately 0.11% of Humana at the end of the most recent quarter.

FronTier Capital Management Co.LLC在第二季度收購了Humana Inc.(紐約證券交易所代碼:HUM-GET Rating)的一個新頭寸,該公司在最近提交給美國證券交易委員會的文件中説。該公司收購了這家保險公司137,088股股票,價值約64,167,000美元。Humana佔Frontier Capital Management Co.LLC所持股份的0.7%,是該公司第27大持股。截至最近一個季度末,FronTier Capital Management Co.LLC擁有Humana約0.11%的股份。

Several other institutional investors and hedge funds have also bought and sold shares of the business. Riverview Trust Co purchased a new position in shares of Humana in the 1st quarter valued at approximately $32,000. Transcend Capital Advisors LLC lifted its stake in shares of Humana by 18.3% in the 1st quarter. Transcend Capital Advisors LLC now owns 587 shares of the insurance provider's stock valued at $255,000 after purchasing an additional 91 shares during the period. Townsend & Associates Inc purchased a new position in shares of Humana in the 2nd quarter valued at approximately $206,000. Krane Funds Advisors LLC lifted its stake in shares of Humana by 4.2% in the 1st quarter. Krane Funds Advisors LLC now owns 889 shares of the insurance provider's stock valued at $387,000 after purchasing an additional 36 shares during the period. Finally, Private Advisor Group LLC lifted its stake in shares of Humana by 32.3% in the 2nd quarter. Private Advisor Group LLC now owns 15,520 shares of the insurance provider's stock valued at $7,265,000 after purchasing an additional 3,788 shares during the period. Hedge funds and other institutional investors own 93.50% of the company's stock.

其他幾家機構投資者和對衝基金也買賣了該公司的股票。Riverview Trust Co在第一季度購買了Humana的新頭寸,價值約3.2萬美元。Transcend Capital Advisors LLC在第一季度增持了Humana 18.3%的股份。Transcend Capital Advisors LLC在此期間又購買了91股,現在擁有587股這家保險公司的股票,價值255,000美元。Townsend&Associates Inc.在第二季度購買了Humana的新頭寸,價值約20.6萬美元。Krane Funds Advisors LLC在第一季度增持了Humana 4.2%的股份。Krane Funds Advisors LLC現在擁有889股這家保險公司的股票,價值38.7萬美元,在此期間又購買了36股。最後,Private Advisor Group LLC在第二季度增持了32.3%的Humana股票。Private Advisor Group LLC在此期間額外購買了3,788股,現在擁有15,520股這家保險提供商的股票,價值7,265,000美元。對衝基金和其他機構投資者持有該公司93.50%的股票。

Get
到達
Humana
哈門那
alerts:
警報:

Analyst Upgrades and Downgrades

分析師升級和下調評級

HUM has been the subject of a number of research analyst reports. SVB Leerink raised their target price on Humana from $535.00 to $540.00 and gave the company an "outperform" rating in a research note on Thursday, July 28th. Oppenheimer raised their price objective on Humana from $520.00 to $550.00 and gave the company an "outperform" rating in a research report on Friday, September 16th. Morgan Stanley raised Humana from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $494.00 to $549.00 in a research report on Tuesday, September 20th. Deutsche Bank Aktiengesellschaft raised their price objective on Humana from $450.00 to $514.00 in a research report on Thursday, July 28th. Finally, Royal Bank of Canada raised their price objective on Humana from $541.00 to $544.00 and gave the company an "outperform" rating in a research report on Tuesday, September 20th. Four research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $519.28.

HUM已成為多份研究分析師報告的主題。7月28日週四,SVB Leerink在一份研究報告中將Humana的目標價從535.00美元上調至540.00美元,並給予該公司“跑贏大盤”的評級。奧本海默將Humana的目標價從520.00美元上調至550.00美元,並在9月16日星期五的一份研究報告中給出了該公司“跑贏大盤”的評級。9月20日,摩根士丹利在一份研究報告中將Humana的評級從持平上調至增持,並將該公司的目標價從494.00美元上調至549.00美元。德意志銀行Aktiengesellschaft在7月28日星期四的一份研究報告中將Humana的目標價從450.00美元上調至514.00美元。最終,加拿大皇家銀行將Humana的目標價從541.00美元上調至544.00美元,並在9月20日(星期二)的一份研究報告中給出了該公司“跑贏大盤”的評級。4名研究分析師對該股的評級為持有,13名分析師對該公司的評級為買入。根據MarketBeat.com的數據,該公司的平均評級為“適度買入”,共識目標價為519.28美元。

Humana Stock Performance

Humana股票表現

Shares of HUM traded down $4.47 during trading hours on Thursday, hitting $489.34. The stock had a trading volume of 3,235 shares, compared to its average volume of 992,934. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.53 and a quick ratio of 1.53. Humana Inc. has a 12 month low of $351.20 and a 12 month high of $514.98. The firm has a market capitalization of $61.93 billion, a PE ratio of 20.16, a PEG ratio of 1.42 and a beta of 0.77. The stock has a fifty day moving average price of $487.66 and a 200 day moving average price of $462.64.
在週四的交易時段,HUM的股價下跌了4.47美元,跌至489.34美元。該股成交量為3235股,而其平均成交量為992,934股。該公司的債務權益比為0.73,流動比率為1.53,速動比率為1.53。Humana Inc.的股價為351.20美元,為12個月低點,12個月高位為514.98美元。該公司的市值為619.3億美元,市盈率為20.16倍,聚乙二醇率為1.42倍,貝塔係數為0.77。該股的50日移動均價為487.66美元,200日移動均價為462.64美元。

Humana (NYSE:HUM – Get Rating) last issued its quarterly earnings data on Wednesday, July 27th. The insurance provider reported $8.67 EPS for the quarter, topping the consensus estimate of $7.67 by $1.00. Humana had a return on equity of 18.42% and a net margin of 3.52%. The company had revenue of $23.66 billion during the quarter, compared to analyst estimates of $23.44 billion. During the same quarter in the previous year, the company posted $6.89 earnings per share. Humana's revenue was up 14.6% compared to the same quarter last year. Analysts anticipate that Humana Inc. will post 25.01 EPS for the current year.

Humana(NYSE:HUM-GET Rating)最近一次發佈季度收益數據是在7月27日星期三。這家保險提供商公佈本季度每股收益為8.67美元,比普遍預期的7.67美元高出1.00美元。Humana的股本回報率為18.42%,淨利潤率為3.52%。該公司本季度營收為236.6億美元,而分析師預期為234.4億美元。去年同期,該公司公佈的每股收益為6.89美元。Humana的收入與去年同期相比增長了14.6%。分析師預計Humana Inc.將公佈本年度每股收益25.01美元。

Humana Dividend Announcement

Humana股息公告

The business also recently announced a quarterly dividend, which will be paid on Friday, October 28th. Investors of record on Friday, September 30th will be given a dividend of $0.7875 per share. The ex-dividend date is Thursday, September 29th. This represents a $3.15 annualized dividend and a yield of 0.64%. Humana's dividend payout ratio (DPR) is presently 12.86%.

該公司最近還宣佈了季度股息,將於10月28日(星期五)支付。9月30日(星期五)登記在冊的投資者將獲得每股0.7875美元的股息。除息日為9月29日(星期四)。這意味着年化股息為3.15美元,收益率為0.64%。Humana的股息支付率(DPR)目前為12.86%。

Insider Activity at Humana

Humana的內幕活動

In related news, insider Joseph C. Ventura sold 1,226 shares of Humana stock in a transaction on Tuesday, September 20th. The stock was sold at an average price of $506.78, for a total transaction of $621,312.28. Following the transaction, the insider now directly owns 3,930 shares in the company, valued at $1,991,645.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.39% of the stock is owned by company insiders.

在相關新聞中,內部人士約瑟夫·C·文圖拉在9月20日星期二的一筆交易中出售了1,226股Humana股票。該股以506.78美元的平均價格出售,總成交金額為621,312.28美元。交易完成後,這位內部人士現在直接持有該公司3930股票,價值1,991,645.40美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過美國證券交易委員會網站。0.39%的股份由公司內部人士持有。

About Humana

關於胡馬納

(Get Rating)

(獲取評級)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Humana Inc.及其子公司在美國作為一家健康和福祉公司運營。它通過三個部門運營:零售、集團和專業以及醫療保健服務。該公司為個人提供醫療和補充福利計劃。它還與醫療保險和醫療補助服務中心簽訂了合同,以管理有限收入新符合資格的過渡處方藥計劃計劃;並與各州簽訂了提供醫療補助、雙重資格和長期支持服務福利的合同。

Featured Stories

專題報道

  • Get a free copy of the StockNews.com research report on Humana (HUM)
  • This Little Known Small Cap Is Up 139%: Is The Stock A Buy?
  • A Trio of Q3 Winners With Room to Run
  • Can HCA Healthcare Weather the Normalization?
  • Can United Natural Foods Fight Both Inflation and the Fed?
  • Mullen Automotive Is Ready To Get In Gear
  • 免費獲取StockNews.com關於Humana的研究報告(嗡嗡)
  • 這個小知名的小盤股上漲了139%:這隻股票是買入的嗎?
  • 第三季度贏家三人組還有運行的空間
  • HCA醫療能否經受住正常化的考驗?
  • 聯合天然食品能同時對抗通脹和美聯儲嗎?
  • 馬倫汽車已做好準備投入使用

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

接受《Humana Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Humana和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論